| Symbol | CSTL |
|---|---|
| Name | CASTLE BIOSCIENCES INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Services-Medical Laboratories |
| Address | 1500 W. PARKWOOD AVE., FRIENDSWOOD, TX 77546 |
| Telephone | 866-788-9007 |
| Fax | — |
| — | |
| Website | https://www.castlebiosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001447362 |
| Description | Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. Additional info from NASDAQ: |
(30% Negative) CASTLE BIOSCIENCES INC (CSTL) Reports Q2 2026 Financial Results
Read moreCastle Biosciences - Castle Biosciences Reports First Quarter 2026 Results
Read moreCastle Biosciences - Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
Read moreCastle Biosciences - New Data at DDW 2026 ShowTissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barretts Esophagus
Read moreCastle Biosciences - Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanomas Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Read moreCastle Biosciences - Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Read moreCastle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Read moreCastle Biosciences - Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Read moreCastle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Read moreDirector MAETZOLD DEREK J 🟡 adjusted position in 9.8K shares (1 derivative) of CASTLE BIOSCIENCES INC (CSTL) at $25.03 Transaction Date: Apr 06, 2026 | Filing ID: 024264
Read more